The rise in the incidence and prevalence of food allergy has been attributed to a confluence of environmental factors brought about by a modern life style, including altered gut microbiota, acting upon genetically susceptible individuals. Central to the development of food allergy is the breakdown of oral tolerance, normally maintained by food allergen-specific T regulatory (TR) cells. However, the mechanisms by which oral tolerance is disrupted remain obscure. By employing a novel genetic murine model of human food allergy involving a gain of function mutation in the IL-4 receptor alpha chain immunotyrosine inhibitory motif (ITIM), we could demonstrate that food allergy is associated with reduced formation of allergen-specific induced TR (iTR) cells. Those that are generated are dysfunctional, failing to prevent sensitization or to suppress active disease. This failure is relaed to their reprogramming into Th2-like cells, a phenomenon that is also observed in TR cells of human food allergic subjects. Abrogation TR cell Th2 reprogramming by TR cell-specific STAT6 deficiency restores the capacity of allergen-specific Il4raF709 TR cells to suppress disease. Food allergic Il4raF709 mice manifest dysregulation of gastrointestinal innate immune pathways, including innate lymphoid cells 2 (ILC2s) and conventional dendritic cells. They also exhibit dysbiotic commensal flora that are pathogenic, evidenced by their promotion of food allergy when transferred into germ-free (GF) mice. Reciprocally, flora of food allergy- tolerant mice prevented disease induction when transplanted into GF Il4raF709 mice. Importantly, Il4raF709 mice exhibited heightened IgA and IgE anti-commensal antibody responses, consistent with an augmented adaptive immune response to gut microbiota. Accordingly, we propose that excessive IL-4R signaling in TR cells in the context of skewed Th2 environment in the gut is a key pathogenic mechanism by which breakdown oral tolerance takes place, resulting in the suppression of allergen-specific TR cell generation and the reprogramming of those cells formed into pathogenic Th2-like cells. We will also propose that a dysregulated, Th2 promoting innate immune response plays a critical role in amplifying disease. Finally, we hypothesize that discrete dysbiotic bacterial communities play a critical pathogenic role in food allergy by eliciting an augmented adaptive immune response to component bacteria, which in turn potentiates sensitization to food allergens. Our proposed studies will identify fundamental mechanisms by which oral tolerance is subverted in food allergy, and will directly impact the development of curative therapies.
Food allergy has become a serious public health concern with an alarming rise in incidence and prevalence in recent years. Development of effective therapies is severely hampered by the lack of thorough understanding of disease mechanisms. Our proposed studies examine how host immune mechanisms that normally enforce tolerance to ingested foods are subverted in food allergic subjects. We will also examine how disease-promoting gut bacterial species may act to promote food allergy. We will identify microbial species that promote or prevent disease with the aim of resetting the gut microbial communities from ones that are pathogenic to others that promote tolerance to foods. These studies will allow the development of novel, effective therapies and prevention strategies to aid patients with food allergy.
| Abdel-Gadir, A; Schneider, L; Casini, A et al. (2018) Oral immunotherapy with omalizumab reverses the Th2 cell-like programme of regulatory T cells and restores their function. Clin Exp Allergy 48:825-836 |
| Rachid, Rima; Chatila, Talal A (2016) The role of the gut microbiota in food allergy. Curr Opin Pediatr 28:748-753 |
| Noval Rivas, Magali; Burton, Oliver T; Oettgen, Hans C et al. (2016) IL-4 production by group 2 innate lymphoid cells promotes food allergy by blocking regulatory T-cell function. J Allergy Clin Immunol 138:801-811.e9 |
| Noval Rivas, Magali; Chatila, Talal A (2016) Regulatory T cells in allergic diseases. J Allergy Clin Immunol 138:639-652 |
